Abstract Library

#4090 Octreotide infusion pump in patients with functional neuroendocrine tumors and refractory hormonal syndromes

Introduction: In patients with metastatic functional neuroendocrine tumors (NETs), symptoms are, sometimes, not adequately controlled with long-acting somatostatin analogues (LASSAs), so patients need to use boost subcutaneous (sc) octreotide injections (inj) daily. However, this approach is not always effective and convenient for the patients.

Conference:

Presenting Author: Thuringer J

Authors: Thuringer J, Parker G, Sarma A, Hayes A, Mandair D,

Keywords: carcinoid syndrome, VIPoma, Octreotide, pump, refractory, subcutaneous,

#3995 Pelvic metastases in patients with neuroendocrine tumors: A rare site of metastases

Introduction: Pelvic metastases (PMs) in patients with neuroendocrine tumors (NETs) are rare and develop predominately in women with small intestinal NETs (Si-NETs). The characteristics of NET related PMs and the efficacy of different management options have been poorly investigated.

Conference:

Presenting Author:

Authors: Thuringer J, Tsoli M, Parker G, Sarma A, Panagaki M,

Keywords: pelvic metastases, prognosis, oophorectomy, PRRT,

#3976 Radiologic tumor border status can further stratify patients with pancreatic neuroendocrine tumor

Introduction: Recently, pattern-based classifications of the tumor border of pancreatic neuroendocrine tumor (PanNET) have been attempted by independent groups for patient stratification, which are only available in the post-operative setting.

Conference:

Presenting Author: Ahn B

Authors: Ahn B, Park H, Kim H, Hong S,

Keywords: pancreas, neuroendocrine tumor, pathologic tumor border, radiologic tumor border, survival, prognosis,

#3848 LITESPARK-015 cohort B1 – A phase 2 open-label study of Belzutifan (a HIF-2α inhibitor) monotherapy in patients with von Hippel-Lindau (VHL) disease–associated tumors

Introduction: Patients (pts) with von Hippel-Lindau (VHL) disease need novel targeted therapies. Hypoxia-inducible factor 2α (HIF-2α) is a key oncogenic driver in VHL disease. Belzutifan (MK-6482), a HIF-2α inhibitor, has shown antitumor activity in pts with advanced renal cell carcinoma (RCC) and pancreatic neuroendocrine tumors (pNETs); more data are needed in VHL disease–associated localized tumors.

Conference:

Presenting Author:

Authors: Walter T, Gong K, Nakamura E, Iliopoulos O, Jimenez C,

Keywords: von Hippel-Lindau disease, belzutifan, MK-6482,

#3633 Tumor mutation burden in gastroenteropancreatic neuroendocrine neoplasms

Introduction: Neuroendocrine neoplasms (NENs) are rare tumors with limited treatment options. Microsatellite instability (MSI) and tumor mutation burden (TMB) are novel biomarkers in various tumor types. However, few studies have been performed for these novel biomarkers in gastroenteropancreatic (GEP)- NENs.

Conference:

Presenting Author: Sun Young J

Authors: Sun Young J, Seung Tae K, Young Suk P, Jeeyun L,

Keywords: tumor mutation burden, neuroendocrine tumor, neuroendocrine carcinoma, gastroenteropancreatic neuroendocrine neoplasm,